1.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Ang...
by Dahlöf, Björn
The Lancet (British edition), 2005, Vol.366 (9489), p.895-906
2.
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis
by Cipriani, Andrea, Dr
The Lancet (British edition), 2016, Vol.388 (10047), p.881-890
3.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final result...
by Chiappella, Annalisa
The lancet oncology, 2017, Vol.18 (8), p.1076-1088
4.
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
by CLUMECK, Nathan
AIDS (London), 2014, Vol.28 (8), p.1143-1153
5.
Antiepileptic Dosing for Critically Ill Adult Patients Receiving Renal Replacement Therapy
by Smetana, Keaton S., PharmD
Journal of critical care, 2016, Vol.36, p.116-124
6.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
by Borchmann, Peter
The lancet oncology, 2021, Vol.22 (2), p.223-234
7.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
by Ribrag, Vincent, Dr
The Lancet (British edition), 2016, Vol.387 (10036), p.2402-2411
8.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoprox...
by DeJesus, Edwin
The Lancet (British edition), 2012, Vol.379 (9835), p.2429-2438
9.
The Brazilian health system: history, advances, and challenges
by Paim, Jairnilson, Prof
The Lancet (British edition), 2011, Vol.377 (9779), p.1778-1797
10.
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
by The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
The Lancet (British edition), 2001, Vol.358 (9282), p.605-613
11.
Hypopituitarism
by Higham, Claire E, DPhil
The Lancet (British edition), 2016, Vol.388 (10058), p.2403-2415
12.
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
by Bergenstal, Richard M, Dr
The Lancet (British edition), 2010, Vol.376 (9739), p.431-439
13.
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
by Skoetz, Nicole, MD
The lancet oncology, 2013, Vol.14 (10), p.943-952
14.
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
by Parker, Catriona, PhD
The Lancet (British edition), 2010, Vol.376 (9757), p.2009-2017
15.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, c...
by Gronchi, Alessandro, Dr
The lancet oncology, 2017, Vol.18 (6), p.812-822
16.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-l...
by Rosell, Rafael, Dr
The lancet oncology, 2012, Vol.13 (3), p.239-246
17.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRA...
by Grob, Jean Jacques, Prof
The lancet oncology, 2015, Vol.16 (13), p.1389-1398
18.
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
by Oza, Amit M, Prof
The lancet oncology, 2015, Vol.16 (1), p.87-97
19.
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial
by Liou, Jyh-Ming, MD
The Lancet (British edition), 2016, Vol.388 (10058), p.2355-2365
20.
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
by Cocco, Emiliano
Nature medicine, 2019, Vol.25 (9), p.1422-1427
